Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a solid tumour (confirmed by tissue testing) that has spread or come back, including a specific type of ovarian cancer called high-grade serous ovarian cancer (HGSOC)
- People whose cancer has stopped responding to, or has returned after, all standard treatments that are known to help — or those for whom standard treatment is not suitable, not available, or who have chosen not to pursue it after being fully informed of their options
- For certain parts of the trial focused on ovarian cancer, people who have been confirmed to have HGSOC and whose cancer has stopped responding to, returned after, or cannot tolerate platinum-based chemotherapy
- People who have had any number of previous cancer treatments
- People whose cancer can be measured or assessed through scans or tests
- People who are generally well enough to carry out everyday activities with little or no limitation (based on a standard health scoring system used in cancer care)
Who may not be able to join:
- People who have brain tumours or cancer that has spread to the brain and is currently causing unstable or worsening symptoms
- People who are currently receiving any other cancer treatment, except for hormonal therapy used to block certain hormones
- People who have had major surgery within 3 weeks before starting the study treatment
- People who have difficulty swallowing or have a digestive condition expected to significantly reduce how well the study drug is absorbed (though people with a functioning ileostomy or colostomy may still be considered — confirm with trial site)
- People with serious or uncontrolled heart or blood vessel disease
- People who need to regularly take certain stomach acid-reducing medications (called proton pump inhibitors or H2-receptor antagonists), particularly during the dose-finding part of the trial
- People who are unable to stop taking certain medications that strongly or moderately affect how the body processes drugs (known as CYP3A4 inhibitors or strong inducers) (confirm with trial site)
- People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the treatment period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gozde Colak, PhD, 339-707-5855
Phone: 339) 970-7383
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) of ATX-295; Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.